Hims CEO Andrew Dudum says company is testing BPC-157 and other peptides, planning to offer Sermorelin, Glutathione & NAD+ by 2026. Q2 revenue hit $753M.
August 11, 2026 09:00 AM EDT
Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says
Hims & Hers is laying the groundwork to offer access to six banned consumer wellness peptides, should the FDA lift restrictions that …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Digital health and wellness company Hims & Hers is ready to tap into a multi-billion dollar peptide market if U.S. regulators…
Hims stock inched lower Tuesday, recovering from a late-Monday dive.
Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to a federal…
Backed by a famous cricketer and valued at almost $500 million, Everlab wants to make preventative health mainstream. The science…
FDA advisory panel voted 8-6 to recommend compounding pharmacies access BPC-157, opposing FDA scientists' safety concerns. RFK…
